Molecular Imaging Agents: Targets, Technology, Markets, and Commercial Opportunities
Greystone Associates, October 2012
Driven by advances in molecular probe design and biomarker detection methodologies, new imaging agents that can improve visualization of pathologies and cellular processes are changing the practice of diagnostic medicine. The ability of this new generation of contrast agents to detect metabolic changes at the molecular level has significant potential for improving visualization and quality of care. Targetable and activatable imaging agents are gaining interest for a wide range of diagnostic applications that include cardiology, neurology and soft tissue tumor detection. The number of healthcare conditions that can be effectively imaged noninvasively is expanding as a result of these innovative detection technologies. Targeted and activatable imaging agents offer a unique capability to generate unambiguous images by exploiting specific molecular targets, pathways or cellular processes. This new wave of imaging agents signals a paradigm shift in which the reagents take on new importance.
Highlights:
- Analyzes and assesses emerging imaging diagnostic candidates, their capabilities, benefits, limitations and potential
- Profiles development-stage imaging agents and examines their clinical status and commercial prospects
- Analyzes key industry alliances and partnerships by imaging modality, and examines the impact of next-generation imaging candidates on future imaging markets
- Profiles market participants, their development activity and business strategies
- Evaluates the impact of economic, technology, and regulatory factors on the development and commercialization of emerging imaging agents
Executive Summary
Diagnostic Imaging Market Dynamics
The Imaging Agent Landscape
Key Application Development Factors
Molecular Imaging Agent Marketspace
- Commercial MIAs
- Development Stage MIAs
Market Drivers
Industry Alignment and Competitive Landscape
Diagnostic Imaging Product Segment Analysis
Imaging Agent Product Segments and Commercial Potential
- Antibodies
- Conjugated Radioisotopes
- Lanthanide Chelates
- Metabolic Biomarkers
- Optical Probes
- Nanoparticles
Targeted Imaging Agents
Activatable Imaging Agents
Leading Academic/Research Programs/Centers
MIAs and Imaging Modalities – The Current Picture
MRI
Optical Imaging
PET
SPECT
Ultrasound
Evolution in Imaging Agent Market Segments
Disease Detection
Image-Guided Drug Delivery
Physiological Process Mapping
Therapeutic Screening
Treatment Assessment
Differential Diagnosis
MIAs in Healthcare - Clinical Applications
Physiological Visualization
- Angiogenesis
- Apoptosis
- Inflammation
- Neurology
Disease Detection and Therapeutic Management
- Autoimmunity
- Cardiology
- Neurology
- Oncology
Market Factors
Guidance, Rules and Regulations
Managed Care and Reimbursement
Academic and Private Sector R&D Programs
Alliances & Partnerships
Company Profiles
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network